Eli Lilly and Co. made changes to the purchase agreements with the U.S. government for its neutralizing antibody therapies to treat COVID-19, previously authorized for emergency use. As part of Lilly’s planned transition, the company will only supply bamlanivimab and etesevimab together. Additionally, the bamlanivimab and etesevimab agreement has been modified to enable the supply of etesevimab to complement doses of bamlanivimab the U.S. government already purchased, some of which have...